Your browser doesn't support javascript.
loading
Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?
Acikgoz, Yusuf; Bal, Oznur; Ucar, Gokhan; Durnali, Ayse; Ergun, Yakup; Dirikoc, Merve; Esen, Selin Akturk; Dogan, Mutlu.
Afiliação
  • Acikgoz Y; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Bal O; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Ucar G; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Durnali A; Ankara Dr AY Oncology Training and Research Hospital Department of Medical Oncology, Turkey.
  • Ergun Y; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Dirikoc M; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Esen SA; Ankara City Hospital, Department of Medical Oncology, Health Science University, Turkey.
  • Dogan M; Ankara Dr AY Oncology Training and Research Hospital Department of Medical Oncology, Turkey.
Expert Opin Drug Saf ; 20(5): 611-621, 2021 May.
Article em En | MEDLINE | ID: mdl-33605170
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Toxidermias / Cetuximab / Antineoplásicos Imunológicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Toxidermias / Cetuximab / Antineoplásicos Imunológicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article